Multivisceral Transplantation for the Treatment of Intra-abdominal Tumors

Multivisceral transplant is a viable treatment option for patients with non‐resectable intra‐abdominal fibromatosis

“…Recently, non‐resectable intra‐abdominal fibromatosis involving the mesenteric root has been indicated for MVT. However, given the complex natures of MVT and associated high risks, only a handful of studies have been published (Table ) . The first MVT for intra‐abdominal fibromatosis was reported by Misiakos et al in 1999 .…”

“…Multivisceral transplant (MVT), as the last straw, is a potential treatment for patients with non‐resectable fibromatosis that is beyond conventional surgery. Rare MVT cases have been reported, although the prognosis and predicators are largely unknown . This report aimed to study the survival and recurrence in a series of six patients who had conventionally non‐resectable fibromatosis and underwent MVT.…”

Multivisceral transplantation for abdominal tumors in children: A single center experience and review of the literature

“…While MVT has been performed for a variety of tumors (Table ), the vast majority of reported cases have been in adult patients. Of these, outcomes have been varied, with the longest disease‐free survival seen in patients with primary diagnoses of pancreatic or enteric endocrine tumors, gastrointestinal stromal tumors, sarcomas, and desmoid tumors . Larger cohorts, which included liver‐only and liver‐islet cell transplants for the same indication, have confirmed this trend, with Alessiani et al.…”

“…As the first successful MVT was performed by Dr. Starzl and colleagues in 1987, the indications for MVT have expanded as improved preservation techniques and immunosuppression regimens have made multi‐organ transplantation both more feasible as well as successful long term . Primarily utilized for patients with intestinal dysmotility syndromes, diffuse thrombosis of the splanchnic system, intestinal failure with liver disease, or those who have sustained a catastrophic intra‐abdominal event, experience with MVT as a treatment for unresectable intra‐abdominal tumors remains limited.…”

Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine

“…97 Since then, its shortterm outcomes have improved significantly and indications of either intestinal, liver-intestinal, or multivisceral (full/modified) transplantations 98 have expanded for a wide variety of tumors such as desmoid (Gardner's syndrome), neuroendocrine, adenocarcinoma, schwannoma, lymphoma, and sarcoma that would otherwise be unresectable. [99][100][101][102][103][104][105][106][107][108][109][110][111][112] Currently, there is no standardized indication of intestinal and multivisceral transplantation for neoplastic disease. However, for high-grade malignancies such as adenocarcinoma and lymphoma, the disappointing oncological results in the earlier series obviously warrant deliberate patient selection, if not contraindicated.…”